JP2021504370A - 肝疾患を治療するためのｆｘｒ作動薬 - Google Patents

肝疾患を治療するためのｆｘｒ作動薬 Download PDF

Info

Publication number
JP2021504370A
JP2021504370A JP2020528867A JP2020528867A JP2021504370A JP 2021504370 A JP2021504370 A JP 2021504370A JP 2020528867 A JP2020528867 A JP 2020528867A JP 2020528867 A JP2020528867 A JP 2020528867A JP 2021504370 A JP2021504370 A JP 2021504370A
Authority
JP
Japan
Prior art keywords
dose
tropifexol
nash
liver
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020528867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504370A5 (https=
Inventor
バッドマン，マイケル
ブラス，クリフフォード
ラフィテ，ブライアン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2021504370A publication Critical patent/JP2021504370A/ja
Publication of JP2021504370A5 publication Critical patent/JP2021504370A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020528867A 2017-11-30 2018-11-28 肝疾患を治療するためのｆｘｒ作動薬 Pending JP2021504370A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593084P 2017-11-30 2017-11-30
US62/593,084 2017-11-30
PCT/IB2018/059383 WO2019106550A1 (en) 2017-11-30 2018-11-28 Fxr agonists for the treatment of liver diseases

Publications (2)

Publication Number Publication Date
JP2021504370A true JP2021504370A (ja) 2021-02-15
JP2021504370A5 JP2021504370A5 (https=) 2022-01-06

Family

ID=64959384

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020528867A Pending JP2021504370A (ja) 2017-11-30 2018-11-28 肝疾患を治療するためのｆｘｒ作動薬

Country Status (12)

Country Link
US (2) US20210361638A1 (https=)
EP (1) EP3716977A1 (https=)
JP (1) JP2021504370A (https=)
KR (1) KR20200094175A (https=)
CN (1) CN111356458A (https=)
AU (1) AU2018376904B2 (https=)
CA (1) CA3081656A1 (https=)
IL (1) IL274747A (https=)
MX (1) MX2020005557A (https=)
RU (1) RU2020121222A (https=)
TW (1) TW201936189A (https=)
WO (1) WO2019106550A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021014349A1 (en) * 2019-07-23 2021-01-28 Novartis Ag Treatment comprising fxr agonists
WO2021064575A1 (en) * 2019-09-30 2021-04-08 Novartis Ag Treatment comprising the use of fxr agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500317A (ja) * 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｆｘｒ調節のための組成物および方法
WO2017145040A1 (en) * 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists
WO2017145041A1 (en) * 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists
WO2017145031A1 (en) * 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1734970T3 (pl) * 2004-03-12 2015-05-29 Intercept Pharmaceuticals Inc Leczenie zwłóknienia z zastosowaniem ligandów FXR
AR114930A1 (es) * 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500317A (ja) * 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｆｘｒ調節のための組成物および方法
WO2017145040A1 (en) * 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists
WO2017145041A1 (en) * 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists
WO2017145031A1 (en) * 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. MED. CHEM., vol. 60, no. 24, JPN6020049364, 2017, pages 9960 - 9973, ISSN: 0004977560 *

Also Published As

Publication number Publication date
US20190161483A1 (en) 2019-05-30
AU2018376904A1 (en) 2020-05-21
RU2020121222A3 (https=) 2022-04-19
TW201936189A (zh) 2019-09-16
CN111356458A (zh) 2020-06-30
RU2020121222A (ru) 2021-12-30
WO2019106550A1 (en) 2019-06-06
EP3716977A1 (en) 2020-10-07
MX2020005557A (es) 2020-08-20
KR20200094175A (ko) 2020-08-06
CA3081656A1 (en) 2019-06-06
US20210361638A1 (en) 2021-11-25
AU2018376904B2 (en) 2021-07-22
IL274747A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
JP6986022B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP7053478B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP2017513836A (ja) Ｎａｆｌｄおよびｎａｓｈの治療
KR20190083655A (ko) 간 질환을 치료하는 방법
CN108451941A (zh) 治疗糖尿病的组合物和方法
JP2020533339A (ja) Ｆｘｒアゴニストを含む組合せ
JP2021504370A (ja) 肝疾患を治療するためのｆｘｒ作動薬
JP2022548617A (ja) Ｆｘｒアゴニストを含む処置
CN114502198A (zh) 包括使用fxr激动剂的治疗
TWI906348B (zh) 脂肪性肝疾病之治療劑
JP7048863B2 (ja) 非アルコール性脂肪肝疾患の治療法
HK40049899A (en) Methods for using fxr agonists
HK1257647B (en) Methods for using fxr agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230905